Treatment Selection for Early to Intermediate Hepatocellular Carcinoma

被引：1

作者：

Nouso, Kazuhiro ^{[1
]}

Ohki, Takamasa ^{[2
]}

Yamashita, Tatsuya ^{[3
]}

Takaki, Haruyuki ^{[4
]}

Liu, Chien-Au ^{[5
]}

Kang, Tae Wook ^{[6
]}

Lee, Dong Ho ^{[7
]}

Lee, So Jung ^{[8
]}

Kulkarni, Suyash ^{[9
]}

Shree, Deepa ^{[10
]}

Tanaka, Masatoshi ^{[11
]}

机构：

[1] Okayama City Hosp, Dept Gastroenterol, Okayama 7008558, Japan

[2] Mitsui Mem Hosp, Tokyo 1018643, Japan

[3] Kanazawa Univ, Kanazawa, Ishikawa 9201192, Japan

[4] Hyogo Coll Med, Nishinomiya, Hyogo 6638501, Japan

[5] Taipei Vet Gen Hosp, Taipei 11217, Taiwan

[6] Samsun Med Ctr, Seoul 06351, South Korea

[7] Seoul Natl Univ Hosp, Seoul 03080, South Korea

[8] Asan Med Ctr, Seoul 05505, South Korea

[9] Tata Mem Hosp, Mumbai 400012, Maharashtra, India

[10] Rela Inst & Med Ctr, Chennai 600044, Tamil Nadu, India

[11] Yokokura Hosp, Fukuoka 8390295, Japan

来源：

APPLIED SCIENCES-BASEL | 2020年 / 10卷 / 13期

关键词：

hepatocellular carcinoma; treatments; radiofrequency ablation; molecular target agents; hepatic arterial infusion chemotherapy; RADIOFREQUENCY ABLATION; CHEMOEMBOLIZATION; CHEMOTHERAPY; MANAGEMENT; SORAFENIB;

D O I：

10.3390/app10134607

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

Many guidelines and standard therapies have been published for the treatment of hepatocellular carcinoma (HCC). Multiple options for the treatment of early to intermediate-stage HCC have resulted in several differences between the guidelines. In addition, more than a few non-standard therapies have been used in a real-world clinical setting. Radiofrequency ablation or chemotherapy, including hepatic arterial infusion chemotherapy and molecular target agents, are sometimes selected for the treatment of intermediate HCC, whereas in many guidelines, the recommended therapy for these patients is transcatheter arterial chemoembolization. The present status of these topics is reviewed and summarized.

引用

页数：7

共 29 条

[1] Efficacy of additional radiofrequency ablation after transcatheter arterial chemoembolization for intermediate hepatocellular carcinoma
Azuma, Seishin
Asahina, Yasuhiro
Nishimura-Sakurai, Yuki
Kakinuma, Sei
Kaneko, Shun
Nagata, Hiroko
Goto, Fumio
Ootani, Satoshi
Kawai-Kitahata, Fukiko
Taniguchi, Miki
Murakawa, Miyako
Watanabe, Takako
Tasaka-Fujita, Megumi
Itsui, Yasuhiro
Nakagawa, Mina
Watanabe, Mamoru
[J]. HEPATOLOGY RESEARCH, 2016, 46 (04) : 312 - 319
[2] Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions
Bolondi, Luigi
Burroughs, Andrew
Dufour, Jean-Francois
Galle, Peter R.
Mazzaferro, Vincenzo
Piscaglia, Fabio
Raoul, Jean Luc
Sangro, Bruno
[J]. SEMINARS IN LIVER DISEASE, 2012, 32 (04) : 348 - 359
[3] Efficacy of combination therapy with transcatheter arterial chemoembolization and radiofrequency ablation for intermediate-stage hepatocellular carcinoma
Endo, Kei
Kuroda, Hidekatsu
Oikawa, Takayoshi
Okada, Yohei
Fujiwara, Yudai
Abe, Tamami
Sato, Hiroki
Sawara, Kei
Takikawa, Yasuhiro
[J]. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2018, 53 (12) : 1575 - 1583
[4] Combined resection and radiofrequency ablation versus transarterial embolization for intermediate-stage hepatocellular carcinoma: A propensity score matching study
Espinosa, Wendell
Liu, Yueh-Wei
Wang, Chih-Chi
Lin, Chih-Che
Wang, Jing-Houng
Lu, Sheng-Nan
Hung, Chao-Hung
[J]. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2018, 117 (03) : 197 - 203
[5] EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma (vol 69, pg 182, 2018)
Galle, Peter R.
Forner, Alejandro
Llovet, Josep M.
Mazzaferro, Vincenzo
Piscaglia, Fabio
Raoul, Jean-Luc
Schirmacher, Peter
Vilgrain, Valerie
[J]. JOURNAL OF HEPATOLOGY, 2019, 70 (04) : 817 - 817
[6] Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
Ferlay, J.
Colombet, M.
Soerjomataram, I.
Mathers, C.
Parkin, D. M.
Pineros, M.
Znaor, A.
Bray, F.
[J]. INTERNATIONAL JOURNAL OF CANCER, 2019, 144 (08) : 1941 - 1953
[7] AASLD guidelines for the treatment of hepatocellular carcinoma
Heimbach, Julie K.
Kulik, Laura M.
Finn, Richard S.
Sirlin, Claude B.
Abecassis, Michael M.
Roberts, Lewis R.
Zhu, Andrew X.
Murad, M. Hassan
Marrero, Jorge A.
[J]. HEPATOLOGY, 2018, 67 (01) : 358 - 380
[8] Transarterial chemoembolization using drug eluting beads and subsequent percutaneous MR-guided radiofrequency ablation in the therapy of intermediate sized hepatocellular carcinoma
Hoffmann, Ruediger
Rempp, Hansjoerg
Syha, Roland
Ketelsen, Dominik
Pereira, Philippe L.
Claussen, Claus D.
Clasen, Stephan
[J]. EUROPEAN JOURNAL OF RADIOLOGY, 2014, 83 (10) : 1793 - 1798
[9] Treatment of Intermediate-Stage Hepatocellular Carcinoma in Japan: Position of Curative Therapies
Kariyama, Kazuya
Nouso, Kazuhiro
Wakuta, Akiko
Oonishi, Ayano
Toyoda, Hidenori
Tada, Toshifumi
Hiraoka, Atsushi
Tsuji, Kunihiko
Itobayashi, Ei
Ishikawa, Toru
Takaguchi, Koichi
Tsutsui, Akemi
Shimada, Noritomo
Kumada, Takashi
[J]. LIVER CANCER, 2020, 9 (01) : 41 - 49
[10] Percutaneous Radiofrequency Ablation for Intermediate-Stage Hepatocellular Carcinoma
Kariyama, Kazuya
Wakuta, Akiko
Nishimura, Mamoru
Kishida, Masayuki
Oonishi, Ayano
Ohyama, Atsushi
Nouso, Kazuhiro
Kudo, Masatoshi
[J]. ONCOLOGY, 2015, 89 : 19 - 26

← 1 2 3 →